-
Polatuzumab vedotin, sold
under the
brand name Polivy, is a CD79b-directed antibody-drug
conjugate medication used for the
treatment of
diffuse large...
-
Perjeta (pertuzumab), for HER-2
positive breast cancer.
Polatuzumab vedotin|Polivy (
polatuzumab vedotin), for
diffuse large B-cell lymphoma. Protropin...
- doxorubicin, vincristine, and prednisone) plus rituximab. R-CHP with
polatuzumab vedotin, an antibody-drug conjugate, was
included as a
category 1 preferred...
-
chemotherapy regimens:
tisotumab vedotin Examples:
Sofituzumab vedotin Polatuzumab vedotin (RG7596)
Enfortumab vedotin Pinatuzumab vedotin Lifastuzumab...
-
refractory CD22-positive B-cell
precursor acute lymphoblastic leukemia Polatuzumab vedotin Polivy Genentech,
Roche relapsed or
refractory diffuse large...
-
Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab...
- of
influenza A and
influenza B.
Developed by Shionogi. 2019:
Polivy (
Polatuzumab vedotin-piiq):
Treatment of
diffuse large B-cell
lymphoma when used in...
-
humanized tumor necrosis factor receptor (TNFR)
superfamily member 4
Polatuzumab vedotin Polivy mab
humanized CD79B Y
diffuse large B-cell
lymphoma Ponezumab...
- the ABC
variant often have
mutations in the MYD88, CD79A and CD79B (
polatuzumab vedotin)
genes and
overactive B-cell receptor, toll-like receptor, and...
- –
September 2018 – CD22
Cemiplimab –
Libtayo –
September 2018 – PD-1
Polatuzumab vedotin –
Polivy – June 2019 – CD79B The
bispecific antibodies have arrived...
